Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.34 |
| ▸ | RXRB | P28702 | 2/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | MOGAT2 | Q3SYC2 | 5/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | CSF3R | Q99062 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.31 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20322910 | 0.93 | MOGAT2 (0.34) | RXRARXRBRXRGMOGAT2CSF3R | |
| SCHEMBL19856127 | 0.89 | CSF3R (0.35) | RXRARXRBRXRGLTB4RCSF3R | |
| SCHEMBL19856082 | 0.88 | CNR2 (0.38) | — | |
| SCHEMBL19855948 | 0.88 | MOGAT2 (0.31) | MOGAT2CSF3RCYP2C9 | |
| SCHEMBL20313509 | 0.87 | CNR2 (0.37) | CSF3R | |
| SCHEMBL19855967 | 0.86 | MOGAT2 (0.31) | RXRARXRBRXRGMOGAT2CYP2C9 | |
| SCHEMBL19855959 | 0.84 | MOGAT2 (0.36) | MOGAT2LTB4RCSF3RCYP2C9 | |
| SCHEMBL19855947 | 0.84 | FFAR4 (0.34) | RXRARXRBRXRGMOGAT2LTB4R | |
| SCHEMBL20322623 | 0.83 | RXRA (0.34) | RXRARXRBRXRGMOGAT2HDAC1 | |
| SCHEMBL20407424 | 0.83 | MOGAT2 (0.32) | MOGAT2LTB4RCSF3RCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214615-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT | JNC CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| EP-3351525-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-06-28 | — | — | US | disclosed |
| WO-2018025974-A1 | LIQUID-CRYSTAL DISPLAY ELEMENT AND DISPLAY DEVICE | JNC株式会社 | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | C1S, CCND1, C5 | RXRA 2573/4885RXRB 2829/4885RXRG 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.